DGAP-Adhoc

Biotest AG: Discussions regarding business combination

DGAP-Ad-hoc: Biotest AG / Key word(s): Merger Biotest AG: Discussions regarding business combination 29-March-2017 / 23:26 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Discussions regarding business combination

Dreieich, 29 March 2017. Biotest Aktiengesellschaft and Creat Group Corporation, a leading Chinese investment group, are currently in discussions regarding a potential business combination. Creat is a long-term strategic investor.

Creat Group Corporation indicated certain key parameters of a potential combination to be implemented through a public tender offer for all common and preference shares of Biotest Aktiengesellschaft. The envisaged consideration is EUR 28.50 per ordinary share and EUR 19.00 per preference share of Biotest Aktiengesellschaft.

Any potential transaction is still subject to final negotiations of a business combination agreement and an agreement with Biotest Aktiengesellschaft's majority shareholder, OGEL GmbH, as well as finalization of due diligence and the required financing measures. There can be no assurance that a final agreement between the two parties will be reached or that any such offer will be made.

Biotest Aktiengesellschaft

Board of Management

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.